Randy Fenninger is a Senior Public Policy Advisor in the Washington, D.C. office of Holland & Knight where he specializes in healthcare legislation, regulation and policy. Mr. Fenninger has represented health professionals, institutional providers and medical device manufacturers for over 30 years. He has extensive experience working with Congress, the Executive Branch, independent regulatory agencies and public and private health plans. He advises clients on a variety of health policy issues, with a focus on innovative systems of healthcare delivery and emerging technologies. Mr. Fenninger's work includes technical reimbursement matters, such as coding, coverage and payment determinations. He also represents clients in the not-for-profit sector on public health and biomedical research policy.
His background in public policy began with his four years' work at the American Law Division of the Congressional Research Service. Mr. Fenninger then spent nine years in government relations with the American Medical Association where he developed expertise in Medicare policy and regulation, medical education, physician immigration, biomedical research and public health issues.
Upon leaving the AMA he applied these skills to representing a wide range of health clients before Congress, agencies in the Department of Health and Human Services and public and private health plans. These include physician organizations, outpatient providers, hospitals, ancillary services and manufacturers of prescription drugs and medical devices. A large portion of his practice has involved the complex relationships between the Medicare program and healthcare providers. He has successfully assisted clients with Medicare legislative and regulatory issues worth hundreds of millions of dollars. He has also worked with clients faced with the challenges of private insurance, particularly in the area of the introduction of new medical products.
Mr. Fenninger develops technical reimbursement and coverage strategies for manufacturers of medical devices. He also counsels investors on the impact of public and private health insurance policies on potential investments in the healthcare market.
He has advised not-for-profit health organizations on a number of biomedical research and public health matters, including increased funding for specific areas of federally funded research, cancer screening and patient education.